Andy Pike

12PUBLICATIONS
77CO-AUTHORS
Biologically active moleculesGene and molecular therapyCheminformatics and quantitative structure-activity relationshipsMedical molecular engineering of nucleic acids and proteinsPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Oct 23, 2026
Discovery of a Novel Series of Benzimidazoles/Purines as Potent, Selective and Orally Active Inhibitors of the DNA Polymerase Activity of POLQ.

|Mar 25, 2026
A dihydrouracil CRBN ligand mitigates IMiD associated safety liabilities in heterobifunctional targeted protein degrader.

Monica C Rodrigo-Brenni, Jasper C Komen, Ghaith M Hamza

|Jan 30, 2026
Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate Cancer.

James S Scott, Laura Evans, Peter C Astles

|Dec 13, 2025
Lessons learned in linking PROTACs from discovery to the clinic.

Andy Pike, Esther C Y Lee, Iacovos N Michaelides

|Apr 24, 2025
In Vitro ADME Profiling of PROTACs: Successes, Challenges, and Lessons Learned from Analysis of Clinical PROTACs from a Diverse Physicochemical Space.

Abhishek Srivastava, Andy Pike, Magda Swedrowska

|Dec 10, 2024
Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor.

Jeffrey W Johannes, Amber Y S Balazs, Derek Barratt

Pageof 2

Frequent Collaborators

3 joint publications

Sonja J Gill

3 joint publications

Coura R Diene

3 joint publications

Jeffrey W Johannes

3 joint publications

James S Scott